


# Study Group – Pancreatic Cancer

Development and implementation of a Data Integration System (DIS) for better understanding of pancreatic ductal adenocarcinoma (PDAC) heterogeneity and improvement of personalized therapy approaches in order to support innovative clinical trials.


**Speaker:** Prof. Dr. Roland M. Schmid, Munich

## Concept



**Figure 1:** Overview about the Data Integration System (DIS) including the informed consent, patient reported questionnaire, clinical data, Molecular Tumor Board Reports and future collaborations including biosamples and structured radiology reports (BORN-Project)

## Achievements



**Figure 2:** Data export from PCAB-DIS indicating a) total number of enrolled PDAC Patients, b) age distribution and Quality-of-Life measures such as c) Pain levels and d) Fear of Progression

- » The **data integration system (DIS)** already established at all BZKF sites includes documentation of the consent form and patient questionnaire as well as clinical data that is recorded longitudinally. The modular nature of the DIS enables the system to be continuously adapted to the needs of the study group
- » In **future**, biosample collection and the generation of model systems (e.g. organoids) to support clinical and translation study groups and BZKF study groups (liver tumors) are to be included in the DIS. An interface between DIS and the BORN project is also to be generated.

- Achieved Milestones:**
- » Generation of a pancreatic cancer patient collective of 872 patients
  - » Establishment of the data integration system (DIS)
    - clinical data (longitudinal)
    - analyses of genetic and phenotypic changes (MTB)
    - patient reported questionnaire with epidemiological and person-specific data (demographics, lifestyle, family history, QoL)

## Future Milestones

- » **Recruitment of approx. 500 patients per year across all BZKF-sites.**
- » **Standardization in the collection of patient samples and patient-derived models within the framework of Standard Operating Procedures (SOPs) in collaboration with the Lighthouse *Pre-clinical Models* and the Working Group *Biobanks*.**
- » **Adaptation of the DIS as required for mapping biosamples and models.**
- » **Support of BZKF study groups (liver tumors), clinical and translation study groups as well as national and international clinical studies.**

**Authors:** Maximilian Reichert<sup>1</sup>, Lisa Fricke<sup>1</sup>, Bernd Geißler<sup>2</sup>, Helmut Messmann<sup>2</sup>, Robert Grützmann<sup>3</sup>, Maximilian Brunner<sup>3</sup>, Volker Kunzmann<sup>4</sup>, Julia Mayerle<sup>5</sup>, Georg Beyer<sup>5</sup>, Christina Hackl<sup>6</sup>, Arne Kandulski<sup>6</sup>, Roland M. Schmid<sup>1</sup>

<sup>1</sup>Klinikum rechts der Isar der TU München, <sup>2</sup>Universitätsklinikum Augsburg, <sup>3</sup>Universitätsklinikum Erlangen, <sup>4</sup>Universitätsklinikum Würzburg <sup>5</sup>LMU Klinikum München, <sup>6</sup>Universitätsklinikum Regensburg

